Background and Aims: Golimumab is approved for the treatment of moderate-to-severely active ulcerative colitis. However, there have been no formal trials to assess its utility in Crohn's disease [CD]. Our aim was to determine the efficacy and safety of golimumab in patients with anti-tumour necrosis factor [TNF] refractory CD. Methods: Patients with CD treated with golimumab between 2010 and 2017 were included in a retrospective observational study. The vast majority of patients failed two anti-TNF agents. Clinical response was defined as a significant reduction in symptoms and biochemical markers of CD, and no requirement for surgery or introduction of immune-suppressants. Results: Forty-five patients were included, with a median follow-up of 22 months [interquartile range 12-34] following initiation of golimumab. Induction and maintenance regimens were generally higher than standard dosing with first month cumulative doses of 400 mg and above in 75% of the patients. Monthly maintenance doses ≥200 mg were administered in 52% of patients. Clinical response at 3 months was achieved in 35/45 [77.7%] patients. The cumulative probabilities that patients with an initial response maintained their clinical response for 12 and 36 months after introduction of golimumab were 81% and 64%, respectively. Endoscopic improvement and mucosal healing at 12 months was achieved in 73% and 47% of patients, respectively. Conclusions: This study demonstrates the efficacy of golimumab in anti-TNF refractory CD patients. Further studies should be performed in CD to formally assess the efficacy of golimumab in a randomized controlled trial and to establish the optimal dosing regimen.
Introduction
Golimumab is a fully human, IgG1k monoclonal antibody against tumour necrosis factor [TNF] approved for the treatment of moderate-to-severely active ulcerative colitis [UC] . Data on the efficacy of golimumab in UC have been derived largely from two large, double-blind, randomized, controlled trials, the Program of Ulcerative Colitis Research Studies Utilizing an Investigational Treatment, which was divided into Subcutaneous and Maintenance phases [PURSUIT-SC and PURSUIT-M, respectively].
1,2 Based on these two trials, it was concluded that golimumab is effective for induction and maintenance in patients with moderate-to-severely active UC. The PURSUIT-M trial also revealed a good safety profile for golimumab consistent with the other anti-TNF agents.
Infliximab and adalimumab are very effective when used for induction and maintenance therapy in inflammatory bowel disease [IBD] and have an acceptable safety profile. [3] [4] [5] [6] [7] However, primary nonresponse [PNR] , intolerance and secondary loss of response [sLOR] occur with all available anti-TNF agents. 8 Hence, there remains an unmet need for novel anti-TNF agents. Golimumab is the most recently introduced TNF blocker for the treatment of UC and is different from other available anti-TNF antibodies with regard to affinity for TNF and protein stability. 9 Golimumab is a transgenic, fully human monoclonal IgG1 antibody that targets a unique epitope on the TNF molecule. 9 Preclinical studies have shown that the affinity of golimumab for soluble and transmembrane TNF and its ability to neutralize TNF was greater than infliximab and adalimumab. 10 Golimumab was also demonstrated to be superior in terms of its conformational stability and its ability to inhibit TNF-induced cytotoxicity compared with infliximab and adalimumab. 10 Other potential advantages of golimumab over existing anti-TNF agents include its subcutaneous route of administration and a greater interval between doses.
Based on indirect comparison across clinical trials, all anti-TNF agents appear to be comparable in terms of efficacy and safety. [11] [12] [13] [14] Infliximab, adalimumab and certolizumab pegol have been shown in several pivotal trials to be efficacious for the treatment of Crohn's disease [CD] . [15] [16] [17] However, there have been no formal trials to assess golimumab's efficacy in CD. Our aim was to describe the experience at our centre and assess the efficacy and safety of golimumab use in patients with anti-TNF refractory CD.
Methods

Patient selection
We performed a retrospective observational study at the IBD Centre at Mount Sinai Hospital, University of Toronto [Toronto, Canada], on consecutive patients with CD treated with golimumab between March 2010 and April 2017. The diagnosis of CD was established using standard clinical, endoscopic and histological criteria. All patients with intestinal and/or perianal CD and treated with golimumab with at least 3 months of follow-up were reviewed. Patients treated for other indications including UC, IBD unclassified, pouchitis or extra-intestinal manifestations were excluded.
Data collection
Demographic, clinical and endoscopic data were obtained from the medical records of each subject. The following characteristics were recorded for each patient: age at inclusion and at diagnosis, gender, duration of disease, location and phenotype of CD according to the Montreal classification, 18 
Outcome definitions
The primary outcome was the proportion of patients with 3 months' clinical response after starting golimumab therapy. A clinical response was defined as a significant improvement in the patient's symptoms [abdominal pain and/or stool frequency] as assessed by the patient's physician with the decision to continue golimumab, without introduction of an immunomodulator or steroids, if not taken at inclusion, or surgery.
Secondary outcomes were [1] rates of sustained clinical response at 12 and 36 months and at last follow-up in patients with an initial response, [2] biologic and endoscopic response [defined as a significant reduction in the number of visible ulcerations] and mucosal healing [defined as a lack of any visible ulcerations or friable mucosa], [3] the identification of predictive factors of golimumabinduced clinical response at 6 months and [4] the safety of golimumab. Optimizing therapy by increasing the dose or shortening the interval between doses was not considered a loss of response if it achieved clinical benefit.
Failure to respond was defined by the absence of significant improvement in symptoms, if an additional IBD-related medication [excluding immunomodulator, systemic corticosteroids, etc.] was initiated, or if a patient was referred for surgery. A relapse was defined as a therapeutic failure developing after the initial response was achieved. An adverse event [AE] was defined as an adverse reaction that occurred from the date of inclusion to the last follow-up. Severe AEs were defined as any adverse event that resulted in hospitalization or extension of the hospital stay, was fatal or life threatening, or led to a significant disability
Statistical analysis
Continuous variables were expressed as means with standard deviations [SD] or medians with interquartile range [IQR] and percentages for discrete data. The Kaplan-Meier method was used to assess sustained clinical benefit from golimumab over time. In addition, multiple logistic regression analysis using Cox's regression model was performed. The response to golimumab therapy was the dependent variable, while the independent variables were gender, disease duration, location and disease phenotype, perianal disease, history of bowel resection, concomitant therapy and elevated CRP at baseline. Two subgroups of patients according to the cumulative induction dose administered during the first month [< 300 or ≥ 400 mg] were created and incorporated in the logistic regression. A similar analysis was performed with two subgroups of patients according to the standard regimen [100 mg every 4 weeks] or any regimen with higher doses. Variables with p < 0.05 were used for multivariate analysis. A value of p = 0.05 was considered to be significant.
Results
Fifty-three CD patients treated with golimumab between March 2010 and April 2017 were included in our study. Eight patients were excluded: five treated for other indications [three for UC/IBD unspecified, one for pouchitis and one for pyoderma gangrenosum] and three because of lack of follow-up [ Figure 1 ]. Patients were followed for a median duration of 22 were not considered as treatment failure and treatment was discontinued because of pregnancy and lack of insurance. In six patients [13 .3%], the cause for discontinuing treatment was unknown. In 18 out of 23 patients who experienced loss of response, anti-infliximab antibodies were identified. Two additional patients with positive anti-TNF antibodies discontinued treatment because of an infusion reaction and pregnancy. Forty-four out of 45 patients [97.7%] failed adalimumab. In 38 patients, a cause for discontinuing therapy was documented: sLOR in 19 patients, PNR in 13 patients, AE in four patients, one patient due to pregnancy and one due to patient preference. In 11 patients with evidence of antidrug antibodies to adalimumab, nine discontinued adalimumab therapy because of sLOR and two as a result of an injection reaction. The antibody status was unknown in ten patients who experienced sLOR to adalimumab.
Dosage and therapeutic schedules
Different induction regimens and maintenance schedule of treatment with golimumab were used as determined by the treating physicians [ The failure-free survival curve for treatment in patients with initial response with golimumab is shown in Figure 3 . The cumulative probability to maintain clinical response at 12 and 36 months was 81% and 68.4%, respectively. Eight [22. 8%] out of 35 initial responders discontinued golimumab during follow-up: six for sLOR [two referred for surgery; two switched to ustekinumab; two maintained on systemic steroids] and two due to AEs. Therapeutic dose optimization was attempted in ten [28.5%] primary responders for relapse while on golimumab maintenance therapy. This resulted in clinical improvement in eight [80%] patients. The chosen strategies were re-induction in five patients, shortening of dose interval in four patients and a combination of both strategies in one patient.
Four [40%] out of the ten patients with no clinical response at 3 months remained on golimumab: three [30%] obtained response at 6 months and were still receiving golimumab at their last follow-up and one patient was maintained on golimumab despite no apparent clinical response. of the remaining six patients, three were referred for surgery, one was switched to vedolizumab, one was maintained on systemic glucocorticoids and one was lost to follow-up.
A 
Predictors of clinical response
The independent predictive factors of clinical response at 6 months with golimumab are shown in Table 3 . Both an elevated CRP and a high monthly cumulative maintenance dose [≥200 mg] were associated with clinical response at 6 months. Only a higher dose maintenance regimen sustained significance on multivariate analysis.
Adverse events
Seventeen AEs were reported in 15 [33%] patients treated with golimumab [ Table 4 ]. Severe AEs were recorded in two [4.4%] patients, both for serious infections requiring hospitalization. Golimumab was withdrawn in three [6.6%] patients because of an AE: two for drug-induced lupus reactions and one for infection. Infections were the most frequent events, observed in nine [20%] patients. Patients receiving combination therapy had a significantly higher prevalence of infection compared to patients on golimumab monotherapy [eight vs one, respectively, p = 0.01]. There were two systemic injection reactions. Cutaneous complications included one psoriasiform reaction, two allergic reactions and two local injection site reactions. No cases of tuberculosis infection, demyelination, heart failure, malignancy or death were reported. CRP: C-reactive protein; CD: Crohn's disease; IQR: interquartile range; n: number of patients; TNFα: Tumor necrosis factor alpha.
Discussion
Our study is the first to present data on the use of golimumab in adult patients with CD. We evaluated the use of golimumab in CD patients who had previously failed one or more anti-TNF agents and/or other biologics. Our results provide new evidence that golimumab treatment is associated with a sustained clinical response in the majority of anti-TNF-resistant CD patients. The clinical response was associated with a biological and endoscopic response as well as a good safety profile.
Golimumab is a TNF antagonist approved for use in UC. Based on its mechanism of action, golimumab might be expected to be effective in CD as well. However, there is as yet no literature to support this indication. The only previous publication on the use of golimumab in CD patients was a case series of six paediatric patients treated with golimumab and this reported unsatisfactory therapeutic results. 19 Randomized controlled trials of golimumab have been restricted to patients with UC and, as a result, its use has only been approved in the United States and Canada for UC. However, in Canada, off-label use was allowed as part of a compassionate use programme, typically provided when other approved therapies were not accessible or had already been tried and failed.
Despite the efficacy of infliximab and adalimumab in the treatment of moderate and severe CD, a considerable proportion of patients experience loss of response or develop a serious AE. 20, 21 Moreover, the overall response in patients who receive a second or third anti-TNF is lower than in anti-TNF naive patients. [22] [23] [24] The patients in our cohort had clinical features consistent with very resistant disease associated with a high risk of complications. All but one patient had failed or were intolerant to at least two anti-TNFs and one-third had failed at least three different biologics. Furthermore, over 70% of patients had undergone at least one surgical resection. Notwithstanding these clinical features, more than 70% of patients had sustained clinical response at 1 year. This real-life study of CD patients who were predicted to have been treatment refractory to any new medical treatment provides significant support for the efficacy of golimumab in this 'difficult to treat' group of patients.
Several clinical factors were found to be associated with a 6-month clinical response to golimumab. An association between CRP and clinical outcomes has been observed with infliximab and adalimumab. 25, 26 Baseline elevated CRP has been found to correlate with an increased likelihood of response to infliximab. CRP is a useful biomarker that typically indicates the presence of active inflammation when it is elevated. Patients with a normal baseline CRP are more likely to have other reasons for their symptoms [strictures, bacterial overgrowth or irritable bowel syndrome], preventing them from gaining response to treatment. In our cohort, we identified a similar trend with elevated CRP in golimumab therapy, but the effect was not sustained on multivariate analysis. In contrast, higher maintenance doses remained as a predictor of a better outcome at 6 months. In the PURSUIT maintenance trial in UC, a maintenance dose of 100 mg every 4 weeks was demonstrated to be more effective than 50 mg every 4 weeks and placebo. Based on these results, the FDA recommended the use of 100 mg every 4 weeks as maintenance treatment for UC patients. In our cohort, only one-third of patients received the standard maintenance dose of 100 mg every 4 weeks. The others received higher doses and/or shorter intervals using different regimens. Over half of the patients in our series received a maintenance dose of 200 mg every 2 weeks. There are as yet no data on the utility of using higher doses of golimumab. This is the first study to present results with higher maintenance regimens compared to the standard regimens that were used in the major pivotal trials in UC. The logic behind the use of higher maintenance protocols was based on accumulating data pointing towards improved clinical outcomes with higher serum levels, without an increased risk of AEs. 27, 28 Furthermore, our previous reassuring experience with the use of high doses of infliximab and adalimumab, regarding efficacy and safety, led us to apply the same approach with golimumab. Golimumab serum concentrations can be measured today as part of clinical practice, but little is known about the benefit of measuring golimumab levels. In our study, serum golimumab concentrations were not measured or monitored. A small observational study has provided the first evidence that golimumab serum concentrations are associated with outcomes in UC. 29 Similarly, additional data were provided by Adedokun et al. demonstrating improved clinical and endoscopic responses with higher serum golimumab concentrations. 30 These observations further imply that intensified maintenance regimens, such as used in our patient population, may help achieve better outcomes.
In the PURSUIT-SC induction trial, moderate to severely active UC patients were randomized to receive subcutaneous administration with 400 and 200 mg or 200 and 100 mg golimumab at weeks 0 and 2, respectively, or placebo. 1 The two induction regimens showed similar efficacy. In the present study, more than 75% of the patients received increased induction doses above the standard recommended regimen. Similar to the PURSUIT induction study, higher induction doses were not identified as predictors of clinical response although there was a trend towards higher response rates with higher induction doses [p = 0.09]. Unfortunately, our study was not of sufficient power to explore the influence of loading doses.
According to previous studies, the safety profile of golimumab seems to be consistent with other anti-TNFs available for the treatment of UC. In the only randomized control trial evaluating the safety of golimumab maintenance treatment, the percentages of AEs were not significantly different among subjects receiving placebo, 50 mg or 100 mg golimumab, except for injection site reactions that were significantly more frequent in patients receiving 100 mg. In our study, golimumab was found to be safe, with only two [4.4%] serious AEs requiring hospitalization and three [6.6%] cases of drug withdrawal because of immune reactions or infections. The frequencies of serious AEs and serious infections in our patients were very similar to those presented in the PURSUIT trials. The effect of higher dosing on the frequency of AEs could not be assessed because of the small numbers of events.
Our study has several limitations. The most important is its retrospective design. Secondly, clinical scores were unavailable and clinical response was determined according to the physician's assessment. However, clinical response defined by symptoms, such as patienteported outcomes, is commonly used as a relevant marker of clinical activity. Furthermore, in our study, symptomatic improvement was frequently shown to be accompanied by more objective outcomes such as endoscopic response and improvement in biological markers. Several different induction and maintenance regimens were used, some of which were very high and do not represent standard practice. Despite the heterogeneity, higher maintenance doses were associated with better clinical outcomes suggesting a possible benefit with these regimens, particularly in anti-TNF experienced patients with refractory disease. 10 Currently, there are no head-to-head randomized comparisons of anti-TNF agents, although in two network meta-analyses, golimumab was demonstrated to be equally effective as infliximab or adalimumab in patients with moderate to severe UC. 11, 31 Additional retrospective studies did not find a difference in efficacy between the anti-TNF agents. 12, 32 Our results suggest that golimumab has similar efficacy in patients with CD. Given the lack of clear evidence of superiority of one drug, the choice of an anti-TNF agent should be based on other factors such as route and frequency of administration, cost and patient preference. Safety is generally considered to be comparable between the different anti-TNF drugs. 33 Survey studies suggest that patient choice of TNF antagonist is most influenced by route of administration with a preference for subcutaneous therapies over infusion-based therapies. 24, 35 In conclusion, this is the first study to describe the use of golimumab in patients with CD. Subcutaneous golimumab treatment was effective and safe in a selected cohort of multidrug refractory CD patients with maintenance of clinical response in the majority of patients. High doses were frequently used with apparent clinical benefit compared to standard regimens. The effectiveness of golimumab in CD and the optimal dosing schedule merits further evaluation in large randomized trials.
Funding
None.
Conflict of Interest
TG: none. KB: none. AHS: received research grants from Abbvie, Amgen and Pfizer, Millennium Honorarium for Educational Event Presentations from Abbvie, Janssen, Takeda, and Shire Advisory Board for Abbvie, Actavis, Janssen, Takeda, Pharmascience and Shire. MSS: received research support and consulting fees from Janssen, Abbvie, Takeda and Prometheus.
